Emerging immune targets for the treatment of multiple myeloma

Atif Sohail, Adeela Mushtaq, Ahmad Iftikhar, Zabih Warraich, Sandra E. Kurtin, Pavan Tenneti, Ali McBride, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


We reviewed emerging immune strategies for multiple myeloma (MM) therapy excluding US FDA approved drugs. In relapsed refractory MM, isatuximab (anti-CD38) monotherapy achieved overall response (OR) of 24%. Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab. We included seven clinical trials on chimeric antigen receptor (CAR) T cells. CAR T-cell targets include BCMA, CD19, KLC and CD138. A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.

Original languageEnglish (US)
Pages (from-to)265-282
Number of pages18
Issue number4
StatePublished - 2018


  • adoptive cell therapy
  • antibodies
  • antibody therapeutics
  • chimeric antigen T cells
  • immunotherapy
  • multiple myeloma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Emerging immune targets for the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this